Modality
Multispecific
MOA
RAS(ON)i
Target
CGRP
Pathway
PD-1/PD-L1
MG
Development Pipeline
Preclinical
~Jun 2018
→ ~Sep 2019
Phase 1
~Dec 2019
→ ~Mar 2021
Phase 2
~Jun 2021
→ ~Sep 2022
Phase 3
~Dec 2022
→ ~Mar 2024
NDA/BLA
Jun 2024
→ Mar 2030
NDA/BLACurrent
NCT05001463
403 pts·MG
2024-06→2030-03·Completed
403 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-03-234.0y awayPh3 Readout· MG
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2030-03-23 · 4.0y away
MG
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05001463 | NDA/BLA | MG | Completed | 403 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| Fixatuximab | Legend Biotech | Preclinical | CFTR | |
| LEG-9870 | Legend Biotech | Phase 1 | CGRP | |
| ION-1378 | Ionis | NDA/BLA | TROP-2 |